Log in to save to my catalogue

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective tri...

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective tri...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f88cfa70938b4b4aaef5a45e37270992

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer

About this item

Full title

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer

Publisher

England: British Medical Journal Publishing Group

Journal title

BMJ open, 2022-05, Vol.12 (5), p.e048833

Language

English

Formats

Publication information

Publisher

England: British Medical Journal Publishing Group

More information

Scope and Contents

Contents

IntroductionCombination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore, we planned to develop a new combination chemotherapy regimen with oxaliplatin, irinotecan and S...

Alternative Titles

Full title

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_f88cfa70938b4b4aaef5a45e37270992

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f88cfa70938b4b4aaef5a45e37270992

Other Identifiers

ISSN

2044-6055

E-ISSN

2044-6055

DOI

10.1136/bmjopen-2021-048833

How to access this item